Precision Neuroscience Secures $250 Million In Series D Funding Led By Pershing Square And Ackman Oxman

Precision Neuroscience closed an oversubscribed $250 million Series D co-led by Pershing Square Inc., the Ackman Oxman Institute and an undisclosed leading life sciences investment fund, bringing its total funding to $430 million. The brain-computer interface company, led by co-founder and CEO Michael Mager, plans to use the capital to expand clinical programs, advance FDA review of its Layer 7 cortical interface and build commercialization infrastructure. FOUNDERS: Michael Mager & Dr. Benjamin Rapoport INVESTORS: Pershing Square Inc., Ackman Oxman Institute, Duquesne Family Office, B Capital, ARK Invest, Invus, Mubadala Capital, Mirae Asset Capital, Korea Investment Partners, Hitachi Ventures & JSL Health Capital ROUND: Series D AMOUNT: $250,000,000 HQ: New York City, New York #VentureCapital #PrecisionNeuroscience #MichaelMager #TradedVC